Selinexor

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

Aug 21, 2023 → Dec 31, 2025

NCT ID

NCT05597345

About Selinexor

Selinexor is a phase 2 stage product being developed by Karyopharm Therapeutics for Smoldering Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05597345. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07215832	Pre-clinical	Active	—	—	Multiple Myeloma
NCT07200102	Phase 1	Recruiting	Mar 17, 2026	Mar 31, 2031	Multiple Myeloma
NCT05597345	Phase 2	Recruiting	Aug 21, 2023	Dec 31, 2025	Smoldering Multiple Myeloma
NCT04562870	Phase 2	Active	Mar 17, 2021	Sep 1, 2026	Myelofibrosis
NCT04355676	Phase 2	Withdrawn	Apr 30, 2020	Aug 30, 2020	Coronavirus Infection
NCT04349098	Phase 2	Completed	Apr 17, 2020	Oct 5, 2020	Coronavirus Infection
NCT03627403	Phase 2	Terminated	May 10, 2019	Mar 5, 2025	Primary Myelofibrosis
NCT03466827	Phase 2	UNKNOWN	Oct 12, 2017	Jul 1, 2020	Thymoma
NCT02431351	Phase 2	Withdrawn	Nov 1, 2015	May 1, 2019	Myelodysplastic Syndrome
NCT02402764	Phase 2	Completed	Jul 8, 2015	Jun 6, 2019	Breast Cancer
NCT02351505	Phase 2	Terminated	May 1, 2015	Mar 1, 2016	Recurrent Small Cell Lung Carcinoma
NCT02314247	Phase 2	Terminated	Feb 1, 2015	Feb 1, 2016	Peripheral T-cell Lymphoma (PTCL)
NCT02367690	Phase 1/2	Withdrawn	Jan 1, 2015	Sep 1, 2015	Diabetic Foot Ulcers
NCT02138786	Phase 2	Terminated	Nov 14, 2014	Aug 31, 2016	Richter's Transformation
NCT02120222	Phase 1	Completed	Aug 22, 2014	Apr 8, 2018	Recurrent Melanoma
NCT02250885	Phase 2	Completed	Aug 1, 2014	Aug 1, 2016	Carcinoma, Neuroendocrine
NCT02146833	Phase 2	Terminated	May 1, 2014	Apr 1, 2016	Prostate Cancer
NCT02025985	Phase 2	Completed	Apr 9, 2014	Mar 29, 2017	Ovarian Carcinoma
NCT01986348	Phase 2	Terminated	Mar 3, 2014	Jan 23, 2020	Glioblastoma

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
Elotuzumab (BMS-901608; HuLuc63)	AbbVie	Phase 2	52
BHQ880	Novartis	Phase 2	52
carfilzomib + Lenalidomide + Dexamethasone + Melphalan	Amgen	Phase 2	51
Denosumab	Amgen	Phase 2	51
Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone	Amgen	Phase 2	51
Elranatamab	Pfizer	Phase 2	51
Nivolumab + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 2	51
Elotuzumab + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 2	51
Dexamethasone + Iberdomide Hydrochloride	Bristol Myers Squibb	Phase 2	51
Linvoseltamab	Regeneron Pharmaceuticals	Phase 2	51
Linvoseltamab + Daratumumab	Regeneron Pharmaceuticals	Phase 3	76
IPH2101	Innate Pharma	Phase 2	44
PD-L1 peptide	IO Biotech	Phase 2	44

Other Products from Karyopharm Therapeutics

Selinexor + Matching placebo for selinexorPhase 3

Selinexor + Selinexor + RuxolitinibPhase 3

Selinexor + Elotuzumab + Pomalidomide + Dexamethasone OralPhase 3

Selinexor + Matching Placebo for selinexorPhase 3

Selinexor + Bortezomib + DexamethasonePhase 3